Celularity makes cell therapy available in Florida under new state law
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- US stock index futures subdued as oil, Treasury yields rise on Iran tensions
- Oil prices steady as traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Dollar hits two-week high, Middle East conflict and rate paths in focus
- Is the ECB’s hawkish shift just beginning to bite? UBS weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies
June 4, 2026 8:00 AM EDTFLORHAM PARK, N.J. and ORLANDO, Fla., June 04, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular therapies, and Fountain Life Management, LLC (Fountain Life), a leading healthy longevity company delivering a next-generation preventive health model through advanced diagnostics, restorative therapeutics, and AI-driven health intelligence, today announced the availability of cenplacel-L, a placental-derived allogeneic investigational cell therapy, for investigational use by licensed physicians in the State of Florida under recently enacted legislation supporting responsible use of regenerative medicine.
This milestone marks the establishment of one of... More
